Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Vietnamese HIV/AIDS Department Announces Funding For Prevention Efforts
Vietnamese officials announced recently that about 678 billion dong, or about $38.7 million, will be allocated for HIV/AIDS prevention efforts in the country in 2009, the VNA/VietnamPlus.com reports. The announcement was made during a press briefing earlier this week held by the Department for HIV/AIDS Prevention and the Vietnam Journalists Association to review Vietnam"s HIV/AIDS efforts in 2008. Health officials at the briefing said that more than 27,000 people living with HIV/AIDS received treatment through one of the 207 district-level clinics put in place last year and that about 6,000 peer educators and health workers distributed information about the disease to 53.8% of the country"s districts.The new funding will help provide antiretroviral treatment to an estimated 32,000 people living with HIV/AIDS. It also will be used to provide post-exposure prophylaxis to health workers. In addition, the funding will allow up to 90% of HIV-positive pregnant women to receive antiretroviral treatment and information about preventing mother-to-child transmission. Last year, 20,260 new HIV cases were reported in Vietnam, of which 7,452 had progressed to AIDS, according to the HIV/AIDS department. The city of Ho Chi Minh reported the largest number of HIV cases with more than 34,000, accounting for more than 25% of the total number of cases in Vietnam (VNA/VietnamPlus.com, 5/12).
generic viagra online
$20 Million NIH Grant To Transform Clinical Research At UIC
The National Institutes of Health has awarded a five year $20 million grant to the University of Illinois at Chicago"s Center for Clinical and Translational Science.
News of the day
Advanced Technologies Pump Growth Into European Cardiac Rhythm Management Market, Affirms Frost & Sullivan, UK
The incidence of cardiovascular disease is rising due to factors such as ageing, obesity, smoking and other cardiac ailments. Each year cardiovascular diseases cause over 4.3 million deaths, accounting for 48 per cent of all mortalities in Europe.
Sexual Health

Accumetrics, Inc. Announces 1000th Patient Enrolled In GRAVITAS Trial

Accumetrics, Inc. announces that it has enrolled its 1,000th patient into its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow(R) Assay Impact on Thrombosis And Safety). The trial is specifically designed to demonstrate the value of providing clinicians with actionable information for patients who are poor responders to clopidogrel (Plavix(R)). The multi-center, placebo controlled trial will determine whether tailored antiplatelet therapy for poor responders, identified based on the results of the company"s VerifyNow P2Y12 Test, reduces major cardiovascular adverse events (e.g., heart attack, stent thrombosis) following percutaneous coronary intervention (PCI). Currently the trial is being conducted at more than 70 sites in the U.S. and Canada, with a total enrollment goal of approximately 2,800 patients. "This is a very significant milestone for Accumetrics as it brings us ever-closer to our goal of demonstrating the value of the VerifyNow System. By identifying and adjusting therapy for patients that are not responding adequately to standard doses of clopidogrel, GRAVITAS will be the largest multi-center clinical trial that links testing with personalized medicine and improved outcomes. We believe that the VerifyNow System will be seen as an integral tool in ensuring that patients receive not only the most appropriate antiplatelet therapy, but also the adequate dose," said Jeff Dahlen, Ph.D, Vice President, Clinical and Regulatory Affairs of Accumetrics, Inc. "We are very proud to reach this milestone, and look forward to completing enrollment soon, and sharing the results." About GRAVITAS The concept of variability in response to antiplatelet therapy has been well established. The question of whether poor response to antiplatelet therapy, as measured by a laboratory test, leads to poor outcomes is also being demonstrated with increased frequency. However, Accumetrics recognizes the need for a study specifically designed to demonstrate the value of providing clinicians with actionable information to improve outcomes for those patients who are poor responders to antiplatelet therapy. As a result, the GRAVITAS study is the first multi-center, placebo-controlled study to determine whether tailored antiplatelet therapy based on the results of the company"s VerifyNow System reduces major cardiovascular adverse events post-PCI. Accumetrics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009